secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2024-07-30T23:59:59+00:00
Accession:  0001125345-24-000141
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics discontinues vobra duo dosing in TAMARACK Phase 2 mCRPC study on IDMC safety recommendation
--------------------------------------------------------------------------------

- IDMC recommended stopping dosing for remaining participants; most had received 8-12 cycles.
- Emerging adverse events from prolonged exposure cited; participants continue safety and survival follow-up.
- Primary endpoint 6-month rPFS data to be presented at ESMO Congress September 2024.
- Company will not hold Q2 2024 earnings call; financial results release expected August 6.
- Investor conference call planned after ESMO presentation to discuss next steps for vobra duo.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534524000141/0001125345-24-000141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534524000141/mgnx-20240730.htm
  HTML page:      https://secwatch.observer/filing/0001125345-24-000141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer